Evidence map›Paper›PMID 25594173›Full record

ArticleCell2015

Variation in the human immune system is largely driven by non-heritable influences.

Petter Brodin, Vladimir Jojic, Tianxiang Gao, Sanchita Bhattacharya, Cesar J Lopez Angel, David Furman, Shai Shen-Orr, Cornelia L Dekker, Gary E Swan, Atul J Butte and 2 more

6 registry-linked trialsAbstract readTwin Study
In one paragraph

Article in Cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 608 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
608citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01987349 phase4completednot on this map

Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 1, 2009

TypeinterventionalSponsorStanford UniversityRan2009 to 2010Enrolled72ConditionsInfluenzaArmsFluzone® (intramuscular), FluMist® (intranasal)
NCT02133781 phase4completednot on this map

U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 1, 2009

TypeinterventionalSponsorStanford UniversityRan2009 to 2009Enrolled51ConditionsInfluenzaArmsFluzone® 2009-2010 Formula, FluMist® 2009-2010 Formula
NCT03020498 phase4completednot on this map

Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire - Years 2 (2010) & 3 (2011)

TypeinterventionalSponsorStanford UniversityRan2010 to 2011Enrolled91ConditionsInfluenzaArmsFluzone, FluMist
NCT03022396 phase4completednot on this map

Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 2, 2010

TypeinterventionalSponsorStanford UniversityRan2010 to 2011Enrolled82ConditionsInfluenzaArmsHigh Dose Fluzone® (intramuscular), Fluzone® (intramuscular)
NCT03022422 phase4completednot on this map

Protective Mechanisms Against a Pandemic Respiratory Virus: B-Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 3, 2011

TypeinterventionalSponsorStanford UniversityRan2011 to 2011Enrolled63ConditionsInfluenzaArmsTIV, High-Dose TIV
NCT04499534 active not recruitingnot on this mapstarted 2019, after this paper: background citation

Influenza Vaccine Study in BRCA1 or BRCA2 Carriers

TypeobservationalSponsorAbramson Cancer Center at Penn MedicineRan2019 to 2027Enrolled50ConditionsBRCA1 Mutation, BRCA2 MutationArmsSeasonal influenza vaccine
3 · Its place in the literature

Who cites it

608 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Immune development in early life.Nature immunology · 2026
    Review

548 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Petter BrodinScience for Life Laboratory, Department of Medicine, Solna, Karolinska Institutet, 17121 Solna, Sweden; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94304, USA; Institute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94304, USA.
Vladimir JojicDepartment of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Tianxiang GaoDepartment of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Sanchita BhattacharyaInstitute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94304, USA.
Cesar J Lopez AngelDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94304, USA; Institute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94304, USA.
David FurmanDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94304, USA; Institute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94304, USA.
Shai Shen-OrrDepartment of Immunology, Faculty of Medicine, Technion, Haifa 31096, Israel.
Cornelia L DekkerDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94304, USA.
Gary E SwanStanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA.
Atul J ButteDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94304, USA; Center for Pediatric Bioinformatics, Lucille Packard Children's Hospital, Stanford University, Stanford, CA 94304, USA.
Holden T MaeckerInstitute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94304, USA; Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA 94304, USA.
Mark M DavisDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94304, USA; Institute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94304, USA; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94304, USA. Electronic address: mmdavis@stanford.edu.

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1RR025744 · NCRR · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2008 to 2011
$22.4M
Vaccination and infection: indicators of immunological health and responsivenessU19AI090019 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2010 to 2015
$17.3M
PHARMACOKINETICS OF NICOTINE IN TWINSR01DA011170 · NIDA · SRI INTERNATIONAL · PI SWAN, GARY E · 1998 to 2002
$1.5M
Opioid Efficacy In Humans: A Twin StudyR01DA023063 · NIDA · STANFORD UNIVERSITY · PI ANGST, MARTIN STEPHAN, CLARK, DAVID J. · 2008 to 2010
$1.4M
Effects of Tobacco Exposure on Immune ResponsesR21ES022153 · NIEHS · STANFORD UNIVERSITY · PI NADEAU, KARI C. · 2013 to 2014
$471k
NCATS NIH HHS UL1 TR001085NCRR NIH HHS UL1 RR025744NIAID NIH HHS AI090019NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI090019NIDA NIH HHS DA011170NIDA NIH HHS DA023063NIDA NIH HHS R01 DA011170NIDA NIH HHS R01 DA023063NIEHS NIH HHS ES022153NIEHS NIH HHS R21 ES022153
6 · The paper itself

Abstract

There is considerable heterogeneity in immunological parameters between individuals, but its sources are largely unknown. To assess the relative contribution of heritable versus non-heritable factors, we have performed a systems-level analysis of 210 healthy twins between 8 and 82 years of age. We measured 204 different parameters, including cell population frequencies, cytokine responses, and serum proteins, and found that 77% of these are dominated (>50% of variance) and 58% almost completely determined (>80% of variance) by non-heritable influences. In addition, some of these parameters become more variable with age, suggesting the cumulative influence of environmental exposure. Similarly, the serological responses to seasonal influenza vaccination are also determined largely by non-heritable factors, likely due to repeated exposure to different strains. Lastly, in MZ twins discordant for cytomegalovirus infection, more than half of all parameters are affected. These results highlight the largely reactive and adaptive nature of the immune system in healthy individuals.

Indexed as

ImmunityTwins, DizygoticTwins, MonozygoticAdolescentAdultAgedAged, 80 and overBlood ProteinsChildCytokinesCytomegalovirus InfectionsHumansInfluenza VaccinesMiddle AgedYoung AdultBlood ProteinsCytokinesInfluenza Vaccines

Identifiers

PMID25594173
PMCPMC4302727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.